{"id":"intensive-bp-treatment-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension/dizziness"},{"rate":null,"effect":"Acute kidney injury"},{"rate":null,"effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The 'Intensive BP treatment group' refers to a clinical trial arm comparing aggressive blood pressure lowering (typically systolic <120 mmHg) versus standard control (typically <140 mmHg) in patients with hypertension and cardiovascular risk factors. The mechanism relies on the principle that lower blood pressure targets reduce vascular damage, atherosclerosis progression, and subsequent cardiovascular complications.","oneSentence":"This is a treatment strategy that uses intensive blood pressure control to reduce cardiovascular events and mortality in hypertensive patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:33.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with cardiovascular disease or high cardiovascular risk"}]},"trialDetails":[{"nctId":"NCT06677970","phase":"PHASE3","title":"Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-10-01","conditions":"Acute Ischemic Stroke","enrollment":176},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":"Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage","enrollment":3500},{"nctId":"NCT06023576","phase":"PHASE2","title":"A Study of Blood Pressure Control During Cancer Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-08-18","conditions":"Breast Cancer, Cardiotoxicity","enrollment":130},{"nctId":"NCT05687344","phase":"PHASE3","title":"Intensive Postpartum Antihypertensive Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-09-01","conditions":"Hypertensive Disorder of Pregnancy","enrollment":60},{"nctId":"NCT06935760","phase":"NA","title":"Optimised Treatment for Hypertension Trial","status":"NOT_YET_RECRUITING","sponsor":"The George Institute","startDate":"2025-08-28","conditions":"Hypertension","enrollment":120},{"nctId":"NCT03354143","phase":"PHASE2","title":"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-04-10","conditions":"Hypertension","enrollment":85},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT03790800","phase":"PHASE3","title":"Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial","status":"COMPLETED","sponsor":"The George Institute for Global Health, China","startDate":"2020-03-20","conditions":"Stroke, Acute, Cerebrovascular Disorders","enrollment":2425},{"nctId":"NCT04205305","phase":"PHASE4","title":"Outcome in Patients Treated with Intraarterial Thrombectomy - OptiMAL Blood Pressure Control (OPTIMAL-BP)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-06-18","conditions":"Ischemic Stroke","enrollment":306},{"nctId":"NCT03264352","phase":"PHASE4","title":"Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"XueQing Yu","startDate":"2018-02-01","conditions":"Diabetes Mellitus, Type 2, Adverse Event, Blood Pressure","enrollment":11414},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT03808311","phase":"NA","title":"Blood Pressure Control Target in Diabetes","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2019-02-24","conditions":"Blood Pressure Control Target in Diabetes","enrollment":12821},{"nctId":"NCT04030234","phase":"NA","title":"Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study","status":"COMPLETED","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2019-09-17","conditions":"Hypertension","enrollment":11255},{"nctId":"NCT04347330","phase":"NA","title":"Cardiovascular Risk Reduction in Atrial Fibrillation Trial","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2020-08-31","conditions":"Atrial Fibrillation, Hypertension","enrollment":1675},{"nctId":"NCT04140110","phase":"NA","title":"Second Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED2)","status":"TERMINATED","sponsor":"The George Institute for Global Health, China","startDate":"2020-07-20","conditions":"Acute Ischemic Stroke","enrollment":816},{"nctId":"NCT04775147","phase":"NA","title":"Intensive Control of Blood Pressure in Acute Ischemic Stroke After Endovascular Therapy on Clinical Outcome (CRISIS I)","status":"TERMINATED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2020-07-03","conditions":"Acute Ischemic Stroke","enrollment":205},{"nctId":"NCT03585595","phase":"PHASE3","title":"Intensive Blood Pressure Intervention in Stroke (IBIS) Trial","status":"WITHDRAWN","sponsor":"Tulane University","startDate":"2018-01-01","conditions":"Ischemic Stroke","enrollment":""},{"nctId":"NCT05690997","phase":"NA","title":"Intensive Blood Pressure Control in Ischaemic Stroke Patients With Severe Cerebral Small Vessel Disease","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2023-01-09","conditions":"Small Vessel Cerebrovascular Disease, Stroke","enrollment":104},{"nctId":"NCT03209258","phase":"NA","title":"The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial","status":"COMPLETED","sponsor":"The George Institute for Global Health, China","startDate":"2017-12-12","conditions":"Cerebral Hemorrhage, Stroke, Hypertension","enrollment":7067},{"nctId":"NCT03666351","phase":"PHASE4","title":"Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-18","conditions":"Aortic Stenosis, Aortic Regurgitation, Hypertension","enrollment":128},{"nctId":"NCT04978649","phase":"PHASE4","title":"Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy","status":"WITHDRAWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-09-01","conditions":"Diabetes Mellitus, Type 2, Blood Pressure","enrollment":""},{"nctId":"NCT05352633","phase":"NA","title":"Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-07-18","conditions":"Blood Pressure","enrollment":710},{"nctId":"NCT05421767","phase":"PHASE4","title":"Renal Nerve Stimulation in Uncontrolled Hypertensive Patients Undergoing Renal Denervation","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-06-24","conditions":"Hypertension","enrollment":60},{"nctId":"NCT01422616","phase":"PHASE3","title":"Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)","status":"COMPLETED","sponsor":"The George Institute","startDate":"2012-03","conditions":"Ischemic Stroke, High Blood Pressure","enrollment":4587},{"nctId":"NCT01206062","phase":"NA","title":"Systolic Blood Pressure Intervention Trial","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-10","conditions":"Hypertension","enrollment":9361},{"nctId":"NCT01852201","phase":"NA","title":"POSITIVE Stroke Clinical Trial","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2013-09","conditions":"Ischemic Stroke","enrollment":33},{"nctId":"NCT01661322","phase":"PHASE3","title":"Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke","status":"TERMINATED","sponsor":"University of Nottingham","startDate":"2009-04","conditions":"Stroke","enrollment":3096},{"nctId":"NCT00241904","phase":"PHASE4","title":"Reducing Total Cardiovascular Risk in an Urban Community","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2006-05","conditions":"Cardiovascular Diseases, Heart Diseases, Coronary Disease","enrollment":525},{"nctId":"NCT01176565","phase":"PHASE3","title":"Antihypertensive Treatment of Acute Cerebral Hemorrhage-II","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2011-05-15","conditions":"Intracerebral Hemorrhage","enrollment":1000},{"nctId":"NCT02300207","phase":"NA","title":"Electroacupuncture is Effective in Cardiac Deconditioning Induced by Head-down Bed Rest","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2014-07","conditions":"Cardiovascular Abnormalities, Weightlessness","enrollment":20},{"nctId":"NCT01093703","phase":"NA","title":"Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-12","conditions":"Blood Pressure Control, Kidney Transplant Recipient","enrollment":99},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Control of SBP to <120 mmHg"],"phase":"phase_3","status":"active","brandName":"Intensive BP treatment group","genericName":"Intensive BP treatment group","companyName":"China National Center for Cardiovascular Diseases","companyId":"china-national-center-for-cardiovascular-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a treatment strategy that uses intensive blood pressure control to reduce cardiovascular events and mortality in hypertensive patients. Used for Hypertension with cardiovascular disease or high cardiovascular risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}